MX2015005384A - Miembros de union para il-1 beta. - Google Patents

Miembros de union para il-1 beta.

Info

Publication number
MX2015005384A
MX2015005384A MX2015005384A MX2015005384A MX2015005384A MX 2015005384 A MX2015005384 A MX 2015005384A MX 2015005384 A MX2015005384 A MX 2015005384A MX 2015005384 A MX2015005384 A MX 2015005384A MX 2015005384 A MX2015005384 A MX 2015005384A
Authority
MX
Mexico
Prior art keywords
beta
binding members
binding
diagnostics
inflammatory
Prior art date
Application number
MX2015005384A
Other languages
English (en)
Inventor
Stefanie Grabulovski
Titus Kretzschmar
Simone Schmitt
Abdijapar Shamshiev
Thorsten Alexander Schäfer
Original Assignee
Delenex Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delenex Therapeutics Ag filed Critical Delenex Therapeutics Ag
Publication of MX2015005384A publication Critical patent/MX2015005384A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)

Abstract

La presente invención se refiere a un miembro de unión de anti-IL-1 beta y en particular a fragmentos de anticuerpo de unión IL-1 beta de alta potencia monovalente que es altamente estable y soluble. Tales miembros de unión pueden utilizarse en el tratamiento de enfermedades inflamatorias y otras así como también en diagnósticos. También se proporcionan ácidos nucleicos, vectores, células y composiciones relacionados.
MX2015005384A 2012-11-05 2013-11-05 Miembros de union para il-1 beta. MX2015005384A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722532P 2012-11-05 2012-11-05
EP12007503 2012-11-05
PCT/EP2013/073009 WO2014068132A1 (en) 2012-11-05 2013-11-05 Binding members to il-1 beta

Publications (1)

Publication Number Publication Date
MX2015005384A true MX2015005384A (es) 2015-10-09

Family

ID=47146146

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005384A MX2015005384A (es) 2012-11-05 2013-11-05 Miembros de union para il-1 beta.

Country Status (12)

Country Link
US (5) US9404930B2 (es)
EP (2) EP3750917A1 (es)
JP (2) JP6333271B2 (es)
KR (1) KR102345999B1 (es)
CN (1) CN104870015B (es)
BR (1) BR112015009892B1 (es)
CA (1) CA2888583C (es)
HK (1) HK1214150A1 (es)
MX (1) MX2015005384A (es)
PL (1) PL2914287T3 (es)
RU (1) RU2711118C2 (es)
WO (2) WO2014068132A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3750917A1 (en) * 2012-11-05 2020-12-16 Delenex Therapeutics AG Binding members to il-1 beta
MX368325B (es) 2014-08-29 2019-09-27 Pioneer Hi Bred Int Metodos y dispositivos que implican matrices de aceite.
US9078427B1 (en) 2014-08-29 2015-07-14 Pioneer Hi Bred International Inc Method of storing plant embryos
JP6202652B1 (ja) * 2016-12-19 2017-09-27 株式会社ヘルスケアシステムズ 抗エクオール抗体組成物及びその利用
CN107362351B (zh) * 2017-09-04 2020-11-10 上海市儿童医院 Il-36r的拮抗剂在制备镇痛药物中的应用
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
US20220161243A1 (en) 2019-02-28 2022-05-26 Exxonmobil Chemical Patents Inc. Catalyst Compositions and Precursors, Processes for Making the Same and Syngas Conversion Processes
TWI793503B (zh) 2020-01-20 2023-02-21 美商美國禮來大藥廠 抗IL-1β抗體
WO2022136693A1 (en) * 2020-12-23 2022-06-30 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
CN113908589B (zh) * 2021-10-08 2022-09-27 天津工业大学 一种表面印迹抗体的疏水电荷诱导模式膜层析介质及其制备方法
CN116410331B (zh) * 2021-12-31 2024-01-30 合源生物科技(天津)有限公司 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用
CN116068192A (zh) * 2022-01-24 2023-05-05 中国农业大学 一种检测非洲猪瘟病毒抗体的ELISA检测试剂盒以及protein L的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
CN102093477B (zh) 2002-05-22 2014-02-26 艾斯巴技术-诺华有限责任公司 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
CA2509136C (en) * 2003-01-24 2013-10-29 Applied Molecular Evolution, Inc. Human il-1 beta antagonists
EP1851245B1 (en) * 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
BRPI0611765B1 (pt) 2005-06-07 2022-09-27 Esbatech Ag Anticorpo ou fragmento de anticorpo estável e solúvel que se liga especificamente ao tnf-alfa seus usos e composição diagnóstica ou terapêutica
PT2163562E (pt) * 2005-06-21 2013-12-19 Xoma Us Llc Anticorpos de ligação a il 1 beta e respectivos fragmentos
CA2727171A1 (en) * 2008-06-06 2009-12-10 Xoma Technology Ltd. Methods for the treatment of rheumatoid arthritis
GB2461273A (en) 2008-06-24 2009-12-30 Seppo Haekkinen Load monitoring system
GB0811574D0 (en) 2008-06-24 2008-07-30 Trillion Genomics Ltd Characterising planar samples by mass spectrometry
KR101650165B1 (ko) 2008-06-25 2016-08-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 면역결합제의 용해도 최적화
ES2677003T3 (es) 2008-06-25 2018-07-27 Esbatech, An Alcon Biomedical Research Unit Llc Humanización de anticuerpos de conejo utilizando un marco universal de anticuerpos
JP2012502059A (ja) * 2008-09-05 2012-01-26 ゾーマ テクノロジー リミテッド ＩＬ−１β関連疾患を処置または予防するための方法
WO2012034039A2 (en) * 2010-09-10 2012-03-15 Apexigen, Inc. Anti-il-1 beta antibodies and methods of use
EP3750917A1 (en) * 2012-11-05 2020-12-16 Delenex Therapeutics AG Binding members to il-1 beta

Also Published As

Publication number Publication date
KR102345999B1 (ko) 2021-12-30
JP6333271B2 (ja) 2018-06-06
US20170051054A1 (en) 2017-02-23
BR112015009892B1 (pt) 2022-12-27
JP2016503293A (ja) 2016-02-04
US20140134183A1 (en) 2014-05-15
HK1214150A1 (zh) 2016-07-22
US20180362642A1 (en) 2018-12-20
JP6779252B2 (ja) 2020-11-04
BR112015009892A2 (pt) 2017-08-22
CN104870015B (zh) 2019-07-30
EP3750917A1 (en) 2020-12-16
WO2015067636A1 (en) 2015-05-14
WO2014068132A1 (en) 2014-05-08
US20220220195A1 (en) 2022-07-14
EP2914287B1 (en) 2020-03-18
US10626171B2 (en) 2020-04-21
RU2711118C2 (ru) 2020-01-15
CA2888583A1 (en) 2014-05-08
US10077302B2 (en) 2018-09-18
RU2015120450A (ru) 2016-12-27
JP2018113988A (ja) 2018-07-26
EP2914287A1 (en) 2015-09-09
US20200239565A1 (en) 2020-07-30
CN104870015A (zh) 2015-08-26
US11267884B2 (en) 2022-03-08
US9404930B2 (en) 2016-08-02
PL2914287T3 (pl) 2020-09-07
KR20150079753A (ko) 2015-07-08
CA2888583C (en) 2022-03-29

Similar Documents

Publication Publication Date Title
MX2015005384A (es) Miembros de union para il-1 beta.
MX2016012479A (es) Miembros de unión al factor de necrosis tumoral (tnf) alfa.
BR112018067696A2 (pt) membros de ligação à pd-l1
PH12019501438A1 (en) Anti-pd-1 antibody and use thereof
PH12015502819A1 (en) Anti-pd-1 antibody and use thereof
MX2019006362A (es) Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer.
PH12015502293A1 (en) Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
PH12014502527A1 (en) St2 antigen binding proteins
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
MX2012011771A (es) Aptameros para beta-ngf y su uso en el tratamiento de enfermedades y trastornos mediados por beta-ngf.
CA2818969A1 (en) Improved n-terminal capping modules for designed ankyrin repeat proteins
MX369148B (es) Agentes de unión kir3dl2.
EP2614085A4 (en) ANTI-IL-1 ANTIBODIES AND METHOD FOR THEIR USE
TN2012000167A1 (en) Human il-23 antigen binding proteins
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
WO2012031099A3 (en) Anti-cxcl13 antibodies and methods of using the same
MX2017009767A (es) Nuevas proteínas específicas para la angiogénesis.
MY162791A (en) Anti-il-23 antibodies
WO2015058861A8 (en) Bispecific constructs and their use in the treatment of various diseases
WO2014210037A3 (en) A composition of mesenchymal stem cells
UY34662A (es) Acido nucleico y proteina recombinante del gen de la toxina axmi335, vectores, células, composiciones y métodos para proteger plantas
EA201400089A1 (ru) Конститутивно активные мутанты рецептора абк (абсцизовой кислоты)
IN2015DN00344A (es)
MX2015014198A (es) Anticuerpos cuyo objetivo es m-csf.
WO2011085134A3 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer

Legal Events

Date Code Title Description
FG Grant or registration